NeuroSense Therapeutics (NRSN) News Today $1.19 -0.06 (-4.80%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.20 +0.02 (+1.26%) As of 10/10/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRSN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period NeuroSense Announces Promising Alzheimer’s Biomarker Reductions with PrimeCOctober 8 at 12:53 AM | msn.comNeuroSense Therapeutics (NASDAQ:NRSN) Shares Down 1.7% - Time to Sell?October 8 at 3:33 AM | americanbankingnews.comNeuroSense announces ‘positive’ results from Phase-2b PARADIGM studyOctober 7, 2025 | msn.comNeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease BiomarkersOctober 6, 2025 | prnewswire.comNeuroSense Reports Positive Initial Results for Alzheimer’s Drug CandidateSeptember 10, 2025 | tipranks.comNeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived NeuronsSeptember 10, 2025 | prnewswire.comNeuroSense Therapeutics Announces Positive 18-Month Data for PrimeC in ALS StudySeptember 7, 2025 | theglobeandmail.comNeuroSense Therapeutics Secures $500,000 in Premium Private PlacementSeptember 4, 2025 | tipranks.comNeuroSense Therapeutics Reports Promising Phase 2b Study Results for ALS TreatmentSeptember 4, 2025 | tipranks.comNeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market PriceSeptember 4, 2025 | prnewswire.comNeuroSense Therapeutics Ltd. (NRSN) - Yahoo FinanceAugust 22, 2025 | finance.yahoo.comNeuroSense Therapeutics Announces Annual General Meeting for September 2025August 22, 2025 | msn.comNeuroSense reports 20% of people with ALS from Phase 2a study remain on PrimeCAugust 20, 2025 | msn.comNeuroSense Reports Long-Term Safety of PrimeC in ALS StudyAugust 20, 2025 | tipranks.comNeuroSense Provides Business Update and Progress for the First Half of 2025August 1, 2025 | prnewswire.comAward-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and CommunityJuly 22, 2025 | prnewswire.comNeuroSense Therapeutics Releases Q2 2025 Corporate UpdateJuly 10, 2025 | tipranks.comNeurosense Therapeutics Ltd News (NRSN) - Investing.comJuly 2, 2025 | investing.comNeuroSense Completes Key Meeting with Health Canada for ALS Drug ApprovalJune 26, 2025 | tipranks.comD. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy RecommendationMay 14, 2025 | msn.comWhy This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsMay 12, 2025 | benzinga.comNeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market LaunchMay 7, 2025 | prnewswire.comNeuroSense Therapeutics Advances ALS Treatment and Strategic PartnershipApril 24, 2025 | tipranks.comNeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership UpdateApril 24, 2025 | prnewswire.comNeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS TreatmentApril 9, 2025 | prnewswire.comNeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business UpdatesApril 7, 2025 | prnewswire.comNeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology MeetingApril 4, 2025 | prnewswire.comMarket Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS DrugMarch 20, 2025 | businesswire.comNeuroSense Advances PrimeC Commercialization in CanadaMarch 19, 2025 | tipranks.comPESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment LandscapeMarch 17, 2025 | businesswire.comNeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS TreatmentFebruary 19, 2025 | tipranks.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)February 4, 2025 | markets.businessinsider.comNeuroSense regains Nasdaq complianceJanuary 8, 2025 | markets.businessinsider.comNeuroSense Regains Nasdaq Compliance, Strengthens Position for ALS TreatmentJanuary 6, 2025 | tipranks.comNeuroSense Regains Compliance with Nasdaq's Minimum Equity RequirementJanuary 6, 2025 | prnewswire.comNeuroSense files to sell 5.28M ordinary shares for holdersDecember 27, 2024 | markets.businessinsider.comNeuroSense Therapeutics files to sell 5.28M ordinary shares for holdersDecember 27, 2024 | msn.comNeuroSense enters binding term sheet to advance PrimeC for ALSDecember 24, 2024 | markets.businessinsider.comNeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALSDecember 23, 2024 | prnewswire.comNeuroSense Advances ALS Treatment with PrimeC, Boosts Financial PositionDecember 19, 2024 | markets.businessinsider.comNeuroSense Provides Business Update and Third Quarter 2024 Financial ResultsDecember 18, 2024 | prnewswire.comNeuroSense Therapeutics Regains Nasdaq ComplianceDecember 17, 2024 | tipranks.comMaxim Group Downgrades NeuroSense Therapeutics (NRSN)December 17, 2024 | msn.comNeuroSense cut to Hold at Maxim following PrimeC FDA feedbackDecember 16, 2024 | markets.businessinsider.comNeuroSense downgraded to Hold from Buy at MaximDecember 16, 2024 | markets.businessinsider.comNeuroSense Receives FDA Approval for Phase 3 Study of ALS TreatmentDecember 11, 2024 | markets.businessinsider.comNeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeCDecember 11, 2024 | prnewswire.comNeuroSense’s PrimeC Shows Promise in ALS TreatmentDecember 5, 2024 | markets.businessinsider.comNeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALSDecember 4, 2024 | prnewswire.comNeuroSense Therapeutics Announces Securities Purchase AgreementDecember 2, 2024 | markets.businessinsider.com Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRSN Media Mentions By Week NRSN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRSN News Sentiment▼0.580.77▲Average Medical News Sentiment NRSN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRSN Articles This Week▼61▲NRSN Articles Average Week Get the Latest News and Ratings for NRSN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for NeuroSense Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies INKT News Today NRXP News Today DTIL News Today ANL News Today ALGS News Today GNTA News Today ACRV News Today IMMX News Today DRRX News Today ELYM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRSN) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
